GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Price-to-Owner-Earnings

Societal CDMO (Societal CDMO) Price-to-Owner-Earnings : (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Price-to-Owner-Earnings?

As of today (2024-04-28), Societal CDMO's share price is $1.10. Societal CDMO does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Societal CDMO's Price-to-Owner-Earnings or its related term are showing as below:


SCTL's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), Societal CDMO's share price is $1.10. Societal CDMO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.15. Therefore, Societal CDMO's PE Ratio for today is At Loss.

As of today (2024-04-28), Societal CDMO's share price is $1.10. Societal CDMO's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.15. Therefore, Societal CDMO's PE Ratio without NRI for today is At Loss.

During the past 13 years, Societal CDMO's highest PE Ratio without NRI was 72.47. The lowest was 0.00. And the median was 12.71.


Societal CDMO Price-to-Owner-Earnings Historical Data

The historical data trend for Societal CDMO's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Price-to-Owner-Earnings Chart

Societal CDMO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Societal CDMO Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Societal CDMO's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Price-to-Owner-Earnings falls into.



Societal CDMO Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Societal CDMO's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.10/-0.13
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Societal CDMO  (NAS:SCTL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Societal CDMO Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO (Societal CDMO) Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.
Executives
Bryan M. Reasons director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant director C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr director, officer: Chief Executive Officer
James Charles Miller director 490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens director, 10 percent owner C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc director, 10 percent owner 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks director C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz director 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p. 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355